The FDA
has announced the approval of Jynneos Smallpox and Monkeypox Vaccine, Live,
NonReplicating, for the prevention of smallpox and monkeypox disease in adults
18 years of age and older determined to be at high risk for smallpox or
monkeypox infection. This is the only currently FDA-approved vaccine for the
prevention of monkeypox disease. Although naturally occurring smallpox disease
is no longer a global threat, the intentional release of this highly contagious
virus could have a devastating effect.
This
vaccine is also part of the Strategic National Stockpile (SNS), the nation’s
largest supply of potentially life-saving pharmaceuticals and medical supplies
for use in a public health emergency that is severe enough to cause local
supplies to be depleted. The availability of this vaccine in the SNS will help
ensure that the vaccine is accessible in the U.S. if needed.
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
No comments:
Post a comment
Pharmaceutical Microbiology Resources